Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.

Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.

The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.

A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.

An FDA adcom votes in favour of expansion into a multiple myeloma precursor.

Starglo isn't applicable to a US population, an adcom rules.

The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.